BlackRock Amends Relay Therapeutics Stake, Signals Continued Confidence
Ticker: RLAY · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1812364
| Field | Detail |
|---|---|
| Company | Relay Therapeutics, Inc. (RLAY) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still owns a big chunk of Relay Therapeutics, signaling institutional confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership in Relay Therapeutics, Inc. as of December 31, 2023. This amendment (Amendment No. 2) indicates BlackRock's continued significant, but passive, stake in the biotechnology company. For investors, this filing confirms that a major institutional investor like BlackRock maintains a substantial position, which can signal confidence in Relay Therapeutics' long-term prospects, even if the exact change in their holding isn't detailed in this snippet.
Why It Matters
This filing shows that BlackRock, a massive institutional investor, still holds a significant position in Relay Therapeutics, which can be a vote of confidence for current and potential shareholders.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate risks or major changes in company control.
Analyst Insight
Investors should note BlackRock's continued passive stake as a sign of institutional confidence, but this filing alone doesn't provide new information for immediate trading decisions.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person, a major institutional investor
- Relay Therapeutics, Inc. (company) — the subject company, a biotechnology firm
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in Relay Therapeutics throughout 2024. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment (Amendment No. 2) to a Schedule 13G filing under the Securities Exchange Act of 1934.
Who is the 'reporting person' in this filing?
The reporting person is BlackRock, Inc., a major institutional investment manager.
What company's securities are the subject of this filing?
The subject company is Relay Therapeutics, Inc., identified by CIK 0001812364 and CUSIP 75943R102.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires filing of this statement was December 31, 2023.
Under which rule is this Schedule 13G/A filed?
This Schedule 13G/A is filed under Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding Relay Therapeutics, Inc. (RLAY).